Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 11 de 11
Filter
Add more filters










Publication year range
1.
Epileptic Disord ; 25(5): 702-711, 2023 Oct.
Article in English | MEDLINE | ID: mdl-37518932

ABSTRACT

OBJECTIVE: Adult patients with epilepsy are confronted with significant psychological and psychosocial burdens. However, the role of psychological intervention to improve quality of life has not been fully established yet. The basis of art therapy is symbolic representations of inner experiences but patients may have difficulty expressing themselves. Here, we investigated utilities of scratch art therapy in Japanese adult patients with epilepsy who feel difficulties in social adaptation. METHODS: Seven adult epilepsy patients (four males, age: 32.1 ± 9.9, mean ± SD) treated in epilepsy clinic of our hospital, who complained of psychosocial problems and underwent psychotherapy sessions combined with art therapy, were included. Six patients had focal epilepsy and two of them were sequelae of encephalitis. They were comorbid with depression, mood disorders, anxiety, memory disturbance, and insomnia. Psychotherapy sessions were scheduled at the same day of their clinic visit, every 4-12 weeks, 60 min per day, and art therapy was performed as a part (up to 30 min, in accord with the condition of the patient) of each session. Scratch art therapy was performed by using ready-made publications. Each patient selected favorite motives of figure out of several options suggested by the therapist. RESULTS: All patients quickly adapted themselves to scratch art therapy and verbally expressed their hidden emotions during drawing. One female patient with emotional lability appealed that she could stab herself by pointed end of the pen. Three patients added self-motivated lines to the designed draft. Two patients realized problems to be solved and moved to other suitable therapeutic procedures. SIGNIFICANCE: The current case series study demonstrated utilities of scratch art therapy in Japanese adult patients with epilepsy who feel difficulties in social adaptation. Scratch art therapy is easy to introduce in adult epilepsy patients who have trouble expressing themselves or have uncontrollable emotions.

2.
Intern Med ; 56(4): 441-444, 2017.
Article in English | MEDLINE | ID: mdl-28202868

ABSTRACT

We herein report a case of capsular warning syndrome (CWS) that was successfully treated with recombinant tissue plasminogen activator (rt-PA). A 70-year-old woman had repeated stereotyped transient ischemic attacks (TIAs) of right hemiparesis and dysarthria. After hospitalization, argatroban, aspirin, and cilostazol were started but were ineffective. Thirteen hours after the first episode of TIAs, severe symptoms occurred. Magnetic resonance imaging showed acute infarctions in the internal capsule to corona radiata, so we used rt-PA. Since then, the TIAs have not occurred, and the symptoms have considerably improved. This case suggests that rt-PA might be effective and safe for use in treating CWS.


Subject(s)
Cerebral Infarction/drug therapy , Fibrinolytic Agents/therapeutic use , Ischemic Attack, Transient/drug therapy , Tissue Plasminogen Activator/therapeutic use , Cerebral Infarction/complications , Cerebral Infarction/diagnostic imaging , Diffusion Magnetic Resonance Imaging , Dysarthria/etiology , Female , Humans , Internal Capsule/diagnostic imaging , Ischemic Attack, Transient/diagnostic imaging , Ischemic Attack, Transient/etiology , Magnetic Resonance Angiography , Male , Paresis/etiology , Recombinant Proteins/therapeutic use , Syndrome
3.
Mol Brain ; 8(1): 82, 2015 Dec 04.
Article in English | MEDLINE | ID: mdl-26637371

ABSTRACT

BACKGROUND: Alzheimer's disease (AD) is characterized by senile plaques, extracellular deposits composed primarily of amyloid-beta (Aß), and neurofibrillary tangles, which are abnormal intracellular inclusions containing hyperphosphorylated tau. The amyloid cascade hypothesis posits that the deposition of Aß in the brain parenchyma initiates a sequence of events that leads to dementia. However, the molecular process by which the extracellular accumulation of Aß peptides promotes intracellular pathologic changes in tau filaments remains unclear. To elucidate this process, we presumed that astrocytes might trigger neuronal reactions, leading to tau phosphorylation. In this study, we examined AD pathology from the perspective of the astrocyte-neuron interaction. RESULTS: A cytokine-array analysis revealed that Aß stimulates astrocytes to release several chemical mediators that are primarily related to inflammation and cell adhesion. Among those mediators, insulin-like growth factor (IGF)-binding protein 3 (IGFBP-3) was highly upregulated. In AD brains, the expression of IGFBP-3 was found to be increased by western blot analysis, and increased expression of IGFBP-3 was observed in astrocytes via fluorescence microscopy. In addition, we reproduced the increase in IGFBP-3 after treatment with Aß using human astrocytoma cell lines and found that IGFBP-3 was expressed via calcineurin. In AD brains, the activated forms of calcineurin were found to be increased by western blot analysis, and increased expression of calcineurin was observed in astrocytes via fluorescence microscopy. When Ser9 of glycogen synthase kinase-3ß (GSK-3ß) is phosphorylated, GSK-3ß is controlled and tau phosphorylation is suppressed. Aß suppresses the phosphorylation of GSK-3ß, leading to tau phosphorylation. In this study, we found that IGF-Ι suppressed tau phosphorylation induced by Aß, although IGFBP-3 inhibited this property of IGF-Ι. As a result, IGFBP-3 contributed to tau phosphorylation and cell death induced by Aß. CONCLUSIONS: Our study suggested that calcineurin in astrocytes was activated by Aß, leading to IGFBP-3 release. We further demonstrated that IGFBP-3 produced by astrocytes induced tau phosphorylation in neurons. Our study provides novel insights into the role of astrocytes in the induction of tau phosphorylation and suggests that IGFBP-3 could be an important link between Aß and tau pathology and an important therapeutic target.


Subject(s)
Alzheimer Disease/pathology , Astrocytes/metabolism , Insulin-Like Growth Factor Binding Protein 3/metabolism , Alzheimer Disease/metabolism , Amyloid beta-Peptides/metabolism , Animals , Astrocytes/drug effects , Astrocytes/pathology , Astrocytoma/genetics , Astrocytoma/pathology , Blotting, Western , Brain/drug effects , Brain/metabolism , Brain/pathology , Calcineurin/metabolism , Cell Line, Tumor , Cell Survival/drug effects , Cells, Cultured , Culture Media/pharmacology , Gene Expression Regulation, Neoplastic/drug effects , Glycogen Synthase Kinase 3/metabolism , Glycogen Synthase Kinase 3 beta , Humans , Insulin-Like Growth Factor Binding Protein 3/genetics , Insulin-Like Growth Factor I/pharmacology , Mice , Microscopy, Fluorescence , Models, Biological , Neurons/drug effects , Neurons/metabolism , Phosphorylation/drug effects , RNA, Messenger/genetics , RNA, Messenger/metabolism , Tacrolimus/pharmacology , Up-Regulation/drug effects , tau Proteins/metabolism
4.
PLoS One ; 10(9): e0131199, 2015.
Article in English | MEDLINE | ID: mdl-26414661

ABSTRACT

Obesity and type 2 diabetes are risk factors of Alzheimer's disease (AD). We reported that a high fat diet (HFD) promotes amyloid precursor protein (APP) cleavage by ß-site APP cleaving enzyme 1 (BACE1) without increasing BACE1 levels in APP transgenic mice. However, the detailed mechanism had remained unclear. Here we demonstrate that HFD promotes BACE1/Adaptor protein-2 (AP-2)/clathrin complex formation by increasing AP-2 levels in APP transgenic mice. In Swedish APP overexpressing Chinese hamster ovary (CHO) cells as well as in SH-SY5Y cells, overexpression of AP-2 promoted the formation of BACE1/AP-2/clathrin complex, increasing the level of the soluble form of APP ß (sAPPß). On the other hand, mutant D495R BACE1, which inhibits formation of this trimeric complex, was shown to decrease the level of sAPPß. Overexpression of AP-2 promoted the internalization of BACE1 from the cell surface, thus reducing the cell surface BACE1 level. As such, we concluded that HFD may induce the formation of the BACE1/AP-2/clathrin complex, which is followed by its transport of BACE1 from the cell surface to the intracellular compartments. These events might be associated with the enhancement of ß-site cleavage of APP in APP transgenic mice. Here we present evidence that HFD, by regulation of subcellular trafficking of BACE1, promotes APP cleavage.


Subject(s)
Adaptor Protein Complex 2/metabolism , Amyloid Precursor Protein Secretases/metabolism , Amyloid beta-Protein Precursor/metabolism , Aspartic Acid Endopeptidases/metabolism , Dietary Fats/pharmacology , Proteolysis/drug effects , Adaptor Protein Complex 2/genetics , Alzheimer Disease/genetics , Alzheimer Disease/metabolism , Alzheimer Disease/pathology , Amino Acid Substitution , Amyloid Precursor Protein Secretases/genetics , Amyloid beta-Protein Precursor/genetics , Animals , Aspartic Acid Endopeptidases/genetics , CHO Cells , Cricetinae , Cricetulus , Dietary Fats/adverse effects , Humans , Mice , Mice, Transgenic , Mutation, Missense , Obesity/genetics , Obesity/metabolism , Obesity/pathology , Protein Transport/drug effects , Protein Transport/genetics
5.
PLoS One ; 8(9): e72796, 2013.
Article in English | MEDLINE | ID: mdl-24023774

ABSTRACT

High fat diet (HFD) is prevalent in many modern societies and HFD-induced metabolic condition is a growing concern worldwide. It has been previously reported that HFD clearly worsens cognitive function in amyloid precursor protein (APP) transgenic mice. On the other hand, we have demonstrated that voluntary exercise in an enriched environment is an effective intervention to rescue HFD-induced ß-amyloid (Aß) deposition and memory deficit. However, it had been unclear whether consumption of HFD after exercising abolished the beneficial effect of exercise on the inhibition of Alzheimer's disease (AD) pathology. To examine this question, we exposed wild type (WT) and APP mice fed with HFD to exercise conditions at different time periods. In our previous experiment, we gave HFD to mice for 20 weeks and subjected them to exercise during weeks 10-20. In the present study, mice were subjected to exercise conditions during weeks 0-10 or weeks 5-15 while being on HFD. Interestingly, we found that the effect of exercise during weeks 0-10 or weeks 5-15 on memory function was not abolished in WT mice even if they kept having HFD after finishing exercise. However, in APP transgenic mice, HFD clearly disrupted the effect of exercise during weeks 0-10 or weeks 5-15 on memory function. Importantly, we observed that the level of Aß oligomer was significantly elevated in the APP mice that exercised during weeks 0-10: this might have been caused by the up-regulation of Aß production. These results provide solid evidence that continuation of exercise is necessary to rescue HFD-induced aggravation of cognitive decline in the pathological setting of AD.


Subject(s)
Amyloid beta-Protein Precursor/metabolism , Diet, High-Fat/adverse effects , Memory Disorders/metabolism , Memory Disorders/therapy , Physical Conditioning, Animal/physiology , Amyloid , Animals , Enzyme-Linked Immunosorbent Assay , Female , Immunoblotting , Male , Mice
6.
Neurosci Lett ; 547: 10-5, 2013 Jun 28.
Article in English | MEDLINE | ID: mdl-23669644

ABSTRACT

Alzheimer's disease (AD) is characterized by the deposition of amyloid-ß (Aß) plaques, senile plaque. The Aß peptide is cleaved from amyloid precursor protein (APP) by ß-secretase and γ-secretase. Until now, many literatures have documented that the high concentration of copper is present in Aß plaques and enhances aggregation of. The APP copper binding domain (CuBD) is located in the N-terminal next to the growth factor-like domain that gets involved in APP homodimerization. Importantly, dimerization of APP has profound effect on Aß production. We investigated whether copper alters the state of APP dimerization and how it affects APP metabolism. Here, we demonstrate that copper enhanced APP dimerization and increased extracellular release of Aß. Moreover, copper chelator, D-penicillamine, suppressed APP dimerization and decreased extracellular release of Aß. These results suggest that the action of copper may be profoundly associated with the pathway of Aß production in AD pathogenesis.


Subject(s)
Alzheimer Disease/metabolism , Amyloid beta-Peptides/metabolism , Amyloid beta-Protein Precursor/metabolism , Copper/metabolism , Protein Multimerization , Amyloid beta-Protein Precursor/chemistry , Blotting, Western , Enzyme-Linked Immunosorbent Assay , Fluorescent Antibody Technique , HEK293 Cells , Humans , Immunoprecipitation
7.
J Biol Chem ; 287(27): 23024-33, 2012 Jun 29.
Article in English | MEDLINE | ID: mdl-22563077

ABSTRACT

Accumulating evidence suggests that some dietary patterns, specifically high fat diet (HFD), increase the risk of developing sporadic Alzheimer disease (AD). Thus, interventions targeting HFD-induced metabolic dysfunctions may be effective in preventing the development of AD. We previously demonstrated that amyloid precursor protein (APP)-overexpressing transgenic mice fed HFD showed worsening of cognitive function when compared with control APP mice on normal diet. Moreover, we reported that voluntary exercise ameliorates HFD-induced memory impairment and ß-amyloid (Aß) deposition. In the present study, we conducted diet control to ameliorate the metabolic abnormality caused by HFD on APP transgenic mice and compared the effect of diet control on cognitive function with that of voluntary exercise as well as that of combined (diet control plus exercise) treatment. Surprisingly, we found that exercise was more effective than diet control, although both exercise and diet control ameliorated HFD-induced memory deficit and Aß deposition. The production of Aß was not different between the exercise- and the diet control-treated mice. On the other hand, exercise specifically strengthened the activity of neprilysin, the Aß-degrading enzyme, the level of which was significantly correlated with that of deposited Aß in our mice. Notably, the effect of the combination treatment (exercise and diet control) on memory and amyloid pathology was not significantly different from that of exercise alone. These studies provide solid evidence that exercise is a useful intervention to rescue HFD-induced aggravation of cognitive decline in transgenic model mice of AD.


Subject(s)
Alzheimer Disease/prevention & control , Amyloid beta-Peptides/genetics , Dietary Fats/pharmacology , Memory Disorders/prevention & control , Physical Conditioning, Animal/physiology , Alzheimer Disease/diet therapy , Alzheimer Disease/genetics , Amyloid beta-Peptides/metabolism , Animal Feed , Animals , Cognition/physiology , Disease Models, Animal , Female , Humans , Hypercholesterolemia/diet therapy , Hypercholesterolemia/genetics , Hyperinsulinism/diet therapy , Hyperinsulinism/genetics , Male , Memory Disorders/diet therapy , Memory Disorders/genetics , Metabolic Diseases/diet therapy , Metabolic Diseases/genetics , Mice , Mice, Transgenic , Neprilysin/metabolism , Obesity/diet therapy , Obesity/genetics
8.
J Neurochem ; 121(6): 964-73, 2012 Jun.
Article in English | MEDLINE | ID: mdl-22443192

ABSTRACT

We have recently reported that Presenilin 1 (PS1), a causative gene of familial Alzheimer disease (AD), down-regulates the expression level of insulin receptor (IR) as well as its signaling through a γ-secretase-independent pathway. PS1 is phosphorylated by glycogen synthase kinase 3 ß at the serine 353 and 357 residues. The main purpose of the present study was to clarify the effect of PS1 phosphorylation on IR/insulin signaling. Here, we demonstrate that the pseudo-phosphorylation mutant of PS1 inhibited IR transcription and reduced IR expression compared with wild-type PS1. Importantly, there was a decrease in expression of IR in AD brains, and the phosphorylation ratio of PS1 was negatively correlated with IR level in human brain samples. In the data from mouse models of AD, IR reduction was not observed at the pre-Aß deposition stage but became apparent in that of post-Aß deposition. Together with our previous reports, these results suggest that phosphorylated PS1 can promote the down-regulation of insulin signaling, which may be a positive feed-forward mechanism inhibiting insulin signaling. As insulin resistance is reported to be a risk factor for sporadic AD, this PS1-mediated regulatory mechanism of brain insulin signaling may be causally associated with AD pathology.


Subject(s)
Alzheimer Disease/metabolism , Insulin/metabolism , Presenilin-1/metabolism , Receptor, Insulin/metabolism , Signal Transduction/physiology , Aged , Aged, 80 and over , Animals , Brain/metabolism , Disease Models, Animal , Down-Regulation , Female , Humans , Male , Mice , Mice, Transgenic , Middle Aged , Phosphorylation
9.
Neurobiol Aging ; 33(5): 1011.e11-23, 2012 May.
Article in English | MEDLINE | ID: mdl-22197104

ABSTRACT

The pathogenesis of Alzheimer's disease (AD) is tightly associated with metabolic dysfunctions. In particular, a potential link between type 2 diabetes (T2DM) and AD has been suggested epidemiologically, clinically, and experimentally, and some studies have suggested that exercise or dietary intervention reduces risk of cognitive decline. However, there is little solid molecular evidence for the effective intervention of metabolic dysfunctions for prevention of AD. In the present study, we established the AD model mice with diabetic conditions through high-fat diet (HFD) to examine the effect of environmental enrichment (EE) on HFD-induced AD pathophysiology. Here, we demonstrated that HFD markedly deteriorated memory impairment and increased ß-amyloid (Aß) oligomers as well as Aß deposition in amyloid precursor protein (APP) transgenic mice, which was reversed by exposure to an enriched environment for 10 weeks, despite the continuation of HFD. These studies provide solid evidence that EE is a useful intervention to ameliorate behavioral changes and AD pathology in HFD-induced aggravation of AD symptoms in APP transgenic mice.


Subject(s)
Amyloid beta-Peptides/metabolism , Dietary Fats/toxicity , Environmental Exposure , Memory Disorders/metabolism , Memory Disorders/prevention & control , Alzheimer Disease/genetics , Alzheimer Disease/metabolism , Alzheimer Disease/therapy , Amyloid beta-Peptides/antagonists & inhibitors , Amyloid beta-Peptides/genetics , Animals , Diabetes Mellitus, Type 2/genetics , Diabetes Mellitus, Type 2/metabolism , Dietary Fats/antagonists & inhibitors , Disease Models, Animal , Female , Humans , Male , Memory Disorders/genetics , Mice , Mice, Transgenic
10.
J Neurochem ; 119(2): 354-63, 2011 Oct.
Article in English | MEDLINE | ID: mdl-21699541

ABSTRACT

Sequential processing of amyloid precursor protein (APP) by ß- and γ-secretase leads to the generation of amyloid-ß (Aß) peptides, which plays a central role in Alzheimer's disease pathogenesis. APP is capable of forming a homodimer through its extracellular domain as well as transmembrane GXXXG motifs. A number of reports have shown that dimerization of APP modulates Aß production. On the other hand, we have previously reported that N-cadherin-based synaptic contact is tightly linked to Aß production. In the present report, we investigated the effect of N-cadherin expression on APP dimerization and metabolism. Here, we demonstrate that N-cadherin expression facilitates cis-dimerization of APP. Moreover, N-cadherin expression led to increased production of Aß as well as soluble APPß, indicating that ß-secretase-mediated cleavage of APP is enhanced. Interestingly, N-cadherin expression affected neither dimerization of C99 nor Aß production from C99, suggesting that the effect of N-cadherin on APP metabolism is mediated through APP extracellular domain. We confirmed that N-cadherin enhances APP dimerization by a novel luciferase-complementation assay, which could be a platform for drug screening on a high-throughput basis. Taken together, our results suggest that modulation of APP dimerization state could be one of mechanisms, which links synaptic contact and Aß production.


Subject(s)
Amyloid beta-Peptides/biosynthesis , Amyloid beta-Protein Precursor/metabolism , Cadherins/pharmacology , Extracellular Space/metabolism , Amyloid Precursor Protein Secretases/metabolism , Blotting, Western , Cadherins/antagonists & inhibitors , Cell Adhesion/drug effects , Dimerization , Extracellular Space/drug effects , HEK293 Cells , Humans , Immunoprecipitation , Indicators and Reagents , Plasmids/genetics , Transfection
11.
J Biol Chem ; 286(28): 25309-16, 2011 Jul 15.
Article in English | MEDLINE | ID: mdl-21622565

ABSTRACT

Presenilin (PS), a causative molecule of familial Alzheimer disease, acts as a crucial component of the γ-secretase complex, which is required to cleave type I transmembrane proteins such as amyloid precursor protein and Notch. However, it also functions through γ-secretase-independent pathways. Recent reports suggested that PS could regulate the expression level of cell surface receptors, including the PDGF and EGF receptors, followed by modulating their downstream pathways via γ-secretase-independent mechanisms. The main purpose of this study was to clarify the effect of PS on expression of the insulin receptor (IR) as well as on insulin signaling. Here, we demonstrate that PS inhibited IR transcription and reduced IR expression, and this was followed by down-regulation of insulin signaling. Moreover, we suggest that neither γ-secretase activity nor Wnt/ß-catenin signaling can reduce the expression of IR, but a PS-mediated increase in the intracellular Ca(2+) level can be associated with it. These results clearly indicate that PS can functionally regulate insulin signaling by controlling IR expression.


Subject(s)
Amyloid Precursor Protein Secretases/metabolism , Calcium Signaling/physiology , Gene Expression Regulation/physiology , Insulin/metabolism , Presenilins/metabolism , Receptor, Insulin/biosynthesis , Amyloid Precursor Protein Secretases/genetics , Animals , Calcium/metabolism , Cells, Cultured , Insulin/genetics , Mice , Mice, Knockout , Presenilins/genetics , Receptor, Insulin/genetics , Wnt Proteins/genetics , Wnt Proteins/metabolism , Wnt Signaling Pathway/physiology , beta Catenin/genetics , beta Catenin/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...